Epalrestat

Overview

Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.

Application

Products | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Glucose Metabolism | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Aldose Reductase

Product Information

• Catalog No.: HY-66009
• CAS No.: 82159-09-9
• Molecular Formula: C15H13NO3S2
• Molecular Weight: 319.40
• Purity: 99.62%
• Storage: -20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2 mg/mL (6.26 mM); Clear solution
• Availability: In-stock

Source

Original product source